Shares of Strides Pharma Science Ltd surged over 3% on July 29, hitting a fresh 52-week high of ₹968 on the NSE after the company reported robust Q1FY26 earnings. The stock was last seen trading at ₹944.70, up 2.42%.
The pharma firm posted a 6.2% YoY rise in revenue from operations to ₹1,119.7 crore for the quarter ended June 30, 2025. Operational PAT grew sharply by 80.6% to ₹114 crore, while reported PAT stood at ₹105.6 crore.
EBITDA rose 14.8% YoY to ₹218.1 crore, with margins improving by 150 basis points to 19.5%. EPS for the quarter came in at ₹12.4.
Management attributed the strong showing to better product mix and cost discipline. CEO Badree Komandur reaffirmed the company’s commitment to expanding R&D investments and targeting $400 million in US sales by FY27–28.
The company also achieved a ₹264 crore net debt reduction and secured a ‘CARE A Positive’ credit rating upgrade.
